Boston Scientific is releasing in Europe its new Promus PREMIER Everolimus-Eluting Platinum Chromium Coronary Stent System. Not yet available in the United States, the stent features a fluorinated co-polymer that releases Everolimus while maintaining flexibility. From the announcement:
The customized Platinum Chromium alloy stent architecture provides strength without compromising flexibility. An enhanced low-profile delivery system features a shorter, more visible tip, dual-layer balloon and Bi-Segment™ inner lumen catheter designed to facilitate precise stent delivery across challenging lesions. The Everolimus drug and fluorinated co-polymer stent coating have been studied in multiple randomized clinical trials demonstrating long-term safety and efficacy. The PLATINUM Workhorse Trial compared the PROMUS Element™ Stent (Platinum Chromium Everolimus-Eluting stent) to the Xience V™ Stent (Cobalt Chromium Everolimus-Eluting stent), and demonstrated that Platinum Chromium technology has superior clinical outcomes between years one and two.
The Promus PREMIER Stent System is currently offered in a matrix of 47 sizes, ranging in diameter from 2.25 mm to 4.00 mm and lengths of 8 mm to 38 mm on a Monorail® catheter platform. This comprehensive offering provides cardiologists and their patients a broad range of options designed to best suit their needs. The Promus PREMIER Stent System is not available for sale in the United States or Japan.